{
    "clinical_study": {
        "@rank": "31836", 
        "arm_group": [
            {
                "arm_group_label": "Rituximab", 
                "arm_group_type": "Active Comparator", 
                "description": "Inj Rituximab 1 gram IV given on day 0 and day 15"
            }, 
            {
                "arm_group_label": "Combination of Rituximab and Cyclophosphamide IV", 
                "arm_group_type": "Active Comparator", 
                "description": "IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effectiveness of rituximab alone vs combination\n      of rituximab and cyclophosphamide in the treatment of pemphigus not responding adequately to\n      routine medications."
        }, 
        "brief_title": "Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pemphigus", 
        "condition_browse": {
            "mesh_term": "Pemphigus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with the diagnosis of pemphigus based on clinical, histopathological and\n             immunological features the following:\n\n          -  Refractory disease defined as continuing extension of old lesions, development of new\n             lesion, or failure of established lesions to begin to heal despite 3 weeks of therapy\n             on 1.5 mg/kg/day of prednisolone or its equivalent with or without the concurrent use\n             of cyclophosphamide 2mg/kg/day for 12 weeks or azathioprine 2.5 mg/kg/day for 12\n             weeks. Patients who fail to respond to 6 DCP/DP are also considered as refractory\n             disease.\n\n        Exclusion Criteria:\n\n          -  Infections- Hepatitis B, Hepatitis C, HIV, active tuberculosis or sepsis.\n\n          -  Abnormal liver function tests and renal function tests\n\n          -  Known cardiac arrhythmia or conduction abnormality\n\n          -  Systolic ejection fraction <40%\n\n          -  Pregnancy and breast feeding\n\n          -  Severely decreased bone marrow functions.\n\n          -  Known history of bladder cancer or hemorrhagic cystitis\n\n          -  Known allergy to cyclophosphamide\n\n          -  Patients of reproductive age group who haven't completed their family\n\n          -  Known hypersensitivity to murine proteins.\n\n          -  Patients who do not consent for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974518", 
            "org_study_id": "9187-PG-2012"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rituximab", 
                "Combination of Rituximab and Cyclophosphamide IV"
            ], 
            "intervention_name": "Rituximab and Cyclophosphamide IV", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pemphigus", 
            "Rituximab", 
            "Rituximab and IV cyclophosphamide combination", 
            "B cell re-population characteristics following Rituximab"
        ], 
        "lastchanged_date": "November 21, 2013", 
        "location": [
            {
                "contact": {
                    "email": "sundogra@hotmail.com", 
                    "last_name": "Sunil Dogra, MBBS/MD/DNB", 
                    "phone": "91-9855005941"
                }, 
                "facility": {
                    "address": {
                        "city": "Chandigarh", 
                        "country": "India", 
                        "zip": "160012"
                    }, 
                    "name": "Post-graduate Institute of Medical Education and Research"
                }, 
                "investigator": {
                    "last_name": "Shraddha Uprety, MBBS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "maitreeye@gmail.com.com", 
                    "last_name": "Shraddha Uprety, MBBS", 
                    "phone": "8727045588"
                }, 
                "contact_backup": {
                    "last_name": "h"
                }, 
                "facility": {
                    "address": {
                        "city": "Chandigarh", 
                        "country": "India", 
                        "zip": "160012"
                    }, 
                    "name": "PGIMER"
                }, 
                "investigator": {
                    "last_name": "Haridaran Anand Shanmugham, MBBS", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A PILOT STUDY TO ASSESS THE EFFICACY OF RITUXIMAB VERSUS COMBINATION OF RITUXIMAB AND INTRAVENOUS CYCLOPHOSPHAMIDE IN THE TREATMENT OF REFRACTORY PEMPHIGUS", 
        "other_outcome": [
            {
                "measure": "To  study  the  difference  in  relapse  rate", 
                "safety_issue": "No", 
                "time_frame": "upto 9 months"
            }, 
            {
                "measure": "to study the total cumulative dose of corticosteroids adminstered and adjuvants required among patients of the 2 treatment groups", 
                "safety_issue": "No", 
                "time_frame": "upto 9 months"
            }
        ], 
        "overall_contact": {
            "email": "sundogra@hotmail.com", 
            "last_name": "Sunil Dogra, MBBS/MD/DNB", 
            "phone": "91-9855005941"
        }, 
        "overall_contact_backup": {
            "last_name": "Sanjeev Handa, MBBS/MD"
        }, 
        "overall_official": {
            "affiliation": "PGIMER", 
            "last_name": "Shraddha Uprety, MBBS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Indian Council of Medical Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary outcome measures being\nTime taken for control of disease activity\nTime taken for achievement of partial remission\nTime taken for achievement of complete remission", 
            "measure": "Study the clinical efficacy of IV rituximab vs IV rituximab and IV cyclophosphamide combination for treatment of refractory pemphigus in terms of early and late end points as defined by the international pemphigus committee", 
            "safety_issue": "No", 
            "time_frame": "upto 9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974518"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Postgraduate Institute of Medical Education and Research", 
            "investigator_full_name": "Uprety Shraddha", 
            "investigator_title": "Junior Resident", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Flowcytometric analysis of CD19+ve27-ve na\u00efve B cells count, CD19+ve27+ve memory B cells count and CD24highCD38high transitional cell count will be performed at baseline, 3rd month, 6th month and  9th month.", 
            "measure": "Study the characteristics of B cell depletion and repopulation following IV rituximab and combination of IV cyclophosphamide with  IV rituximab.", 
            "safety_issue": "No", 
            "time_frame": "upto 9 months"
        }, 
        "source": "Postgraduate Institute of Medical Education and Research", 
        "sponsors": {
            "collaborator": {
                "agency": "Postgraduate Institute of Medical Education and Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Uprety Shraddha", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}